Treatment with HO-1 inducer hemin or Ad-HO-1 markedly reduced the severity of hepatic steatosis, inflammatory infiltration (Figure 1A) and fibrosis (Figure 1B), which was associated with a prominent decrease in serum ALT (Figure 2A), AST (Figure 2B) levels and hepatic hydroxyproline content (Figure 3A). This evidence concerns the gene GPT and fatty liver disease.